BioGaia Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Theresa Agnew

Chief Executive Officer (CEO)

SEK 6.8m

Compensación total

Porcentaje del salario del CEO	19.4%
Permanencia del CEO	1.2yrs
Participación del CEO	n/a
Permanencia media de la dirección	3.5yrs
Promedio de permanencia en la Junta Directiva	3.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Theresa Agnew en comparación con los beneficios de BioGaia?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	SEK 337m
Jun 30 2024	n/a	n/a	SEK 402m
Mar 31 2024	n/a	n/a	SEK 371m
Dec 31 2023	SEK 7m	SEK 1m	SEK 365m

Compensación vs. Mercado: La compensación total de Theresa($USD613.68K) está por debajo de la media de empresas de tamaño similar en el mercado UK ($USD1.45M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Theresa con los resultados de la empresa.

CEO

Theresa Agnew (58 yo)

1.2yrs

Permanencia

SEK 6,750,250

Compensación

Ms. Theresa P. Agnew serves as President of BioGaia AB (publ) since September 2023 and serves as its Chief Executive Officer since 25 September 2023. She is a global business leader with consumer healthcar...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Peter Rothschild	Founder & Chairman	6.6yrs	SEK 1.33m	sin datos
Theresa Agnew	CEO & President	1.2yrs	SEK 6.75m	sin datos
Alexander Kotsinas	Executive VP & CFO	5yrs	SEK 3.07m	0.0030% SEK 317.9k
Ludvig Milesson	Chief Operating Officer	1.6yrs	sin datos	0.0012% SEK 132.7k
Gianfranco Grompone	Chief Scientific Officer and VP of Research & Development	4.8yrs	sin datos	sin datos
Caroline Mofors	Chief Legal Officer	1.8yrs	sin datos	sin datos
Linda Hagglund	Vice President of Marketing	3.5yrs	sin datos	0.0012% SEK 126.3k
Angelika Kjelldorff	Chief HR Officer	5.8yrs	sin datos	0.00049% SEK 52.4k
Sebastian Heimfors	VP & Chief Commercial Officer	2.7yrs	sin datos	sin datos
Jonathan Gromark	Sustainability Manager	no data	sin datos	sin datos
Keitaro Nomura	MD & President of BioGaia Japan Inc.	no data	sin datos	sin datos

3.5yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0GTN se considera experimentado (3.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Peter Rothschild	Founder & Chairman	6.6yrs	SEK 1.33m	sin datos
David E. Dangoor	Independent Deputy Board Chairman	21.8yrs	SEK 590.00k	1.73% SEK 185.1m
Vesa Koskinen	Director	1.5yrs	SEK 275.00k	sin datos
Barbro Friden	Director	1.5yrs	SEK 275.00k	0.00049% SEK 52.4k
Anthon Jahreskog	Independent Director	9.5yrs	SEK 405.00k	0.0040% SEK 427.0k
Vanessa Rothschild	Director	4.5yrs	SEK 275.00k	0.00016% SEK 17.1k
Benedicte Flambard	Director	2.5yrs	SEK 275.00k	sin datos
Outi Armstrong	Director	1.5yrs	SEK 275.00k	sin datos

3.5yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de 0GTN se considera experimentada (3.5 años de antigüedad promedio).

BioGaia Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Vice President of Marketing recently sold kr407k worth of stock

Executive VP & CFO recently sold kr11m worth of stock

BioGaia AB (publ), Annual General Meeting, Apr 26, 2024

Biogaia AB (Publ) Appoints Theresa Agnew as CEO

BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: kr0.36 (vs kr1.01 in 3Q 2023)

BioGaia AB (publ) to Report Q2, 2025 Results on Jul 18, 2025

Vice President of Marketing recently sold kr407k worth of stock

Executive VP & CFO recently sold kr11m worth of stock

Second quarter 2024 earnings released: EPS: kr1.10 (vs kr0.80 in 2Q 2023)

BioGaia AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025

First quarter 2024 earnings released: EPS: kr1.21 (vs kr1.15 in 1Q 2023)

Full year 2023 earnings released: EPS: kr3.62 (vs kr3.70 in FY 2022)

Full year 2023 earnings released: EPS: kr3.62 (vs kr3.70 in FY 2022)

Biogaia AB (Publ) Proposes an Extra Dividend

BioGaia AB (publ) to Report First Half, 2024 Results on Jul 07, 2024

Third quarter 2023 earnings released

BioGaia AB (publ), Annual General Meeting, Apr 26, 2024

Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023

Biogaia AB (Publ) Appoints Theresa Agnew as CEO

BioGaia AB (publ) Introduces BioGaia Prodentis KIDS in Sweden

BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023

Second quarter 2023 earnings released

BioGaia's probiotic Protectis increases SARS-CoV-2 antibody response in adults

Less than half of directors are independent

First quarter 2023 earnings released

BioGaia AB (Publ) Approves Dividend for 2022

Upcoming dividend of kr2.90 per share at 2.8% yield

Full year 2022 earnings released: EPS: kr3.70 (vs kr1.94 in FY 2021)

Independent Director recently bought kr51k worth of stock

Full year 2022 earnings released: EPS: kr3.70 (vs kr1.94 in FY 2021)

BioGaia AB (publ) Proposes Ordinary Dividend

Third quarter 2022 earnings released

Investor sentiment improved over the past week

BioGaia AB (publ) Provides Earnings Guidance for the Third Quarter of 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: kr0.78 (vs kr0.54 in 2Q 2021)

Biogaia AB (publ) Provides Earnings Guidance for the Second Quarter of 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

BioGaia AB (publ) Approves Extra Dividend

First quarter 2022 earnings released

Upcoming dividend of kr14.92 per share

BioGaia AB (publ) Provides Earnings Guidance for the First Quarter of 2022

BioGaia AB (publ) Proposes Dividend, Payable on 13 May 2022

Full year 2021 earnings released: EPS: kr9.72 (vs kr10.07 in FY 2020)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Biogaia AB (Publ) Proposes Ordinary Dividend

BioGaia's Probiotic Reduces Inflammation in Patients with Diverticulitis

BioGaia AB (publ) Announces First Patient Enrolled in Phase II Clinical Study Evaluating BGP345A for the Treatment of Opioid Induced Constipation (OIC-1)

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS kr2.71 (vs kr4.56 in 2Q 2020)

BioGaia AB (publ) (OM:BIOG B) acquired remaining 8% stake in MetaboGen AB for SEK 11.4 million.

Vice President of RA & Legal recently bought kr103k worth of stock

Vice President of RA & Legal recently bought kr103k worth of stock

Vice President of RA & Legal recently bought kr103k worth of stock

Biogaia AB (Publ) Approves Dividend

First quarter 2021 earnings released

Upcoming dividend of kr3.41 per share

Full year 2020 earnings released: EPS kr10.07

New 90-day low: kr419

CEO & President recently bought kr99k worth of stock

Full year 2020 earnings released: EPS kr10.07 (vs kr10.81 in FY 2019)

Revenue beats expectations

New 90-day low: kr444

BioGaia AB (publ) Elects Niklas Ringby as New Board Member

Market bids up stock over the past week

BioGaia AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.144 billion.